Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions

被引:148
作者
Zhao, HH
Herrera, RE
Coronado-Heinsohn, E
Yang, MC
Ludes-Meyers, JH
Seybold-Tilson, KJ
Nawaz, Z
Yee, D
Barr, FG
Diab, SG
Brown, PH
Fuqua, SAW
Osborne, CK
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med, Div Oncol, San Antonio, TX 78284 USA
[2] Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA
[4] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
D O I
10.1074/jbc.M104278200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In a search for novel transcriptional intermediary factors for the estrogen receptor (ER), we used the ligand-binding domain and hinge region of ER as bait in a yeast two-hybrid screen of a cDNA library derived from tamoxifen-resistant MCF-7 human breast tumors from an in vivo athymic nude mouse model. Here we report the isolation and characterization of the forkhead homologue in rhabdomyosarcoma (FKHR), a recently described member of the hepatocyte nuclear factor 3/forkhead homeotic gene family, as a nuclear hormone receptor (NR) intermediary protein. FKHR interacts with both steroid and nonsteroid NRs, although the effect of ligand on this interaction varies by receptor type. The interaction of FKHR with ER is enhanced by estrogen, whereas its interaction with thyroid hormone receptor and retinoic acid receptor is ligand-independent. In addition, FKHR differentially regulates the transactivation mediated by different NRs. Transient transfection of FKHR into mammalian cells dramatically represses transcription mediated by the ER, glucocorticoid receptor, and progesterone receptor. In contrast, FKHR stimulates rather than represses retinoic acid receptor- and thyroid hormone receptor-mediated transactivation. Most intriguingly, overexpression of FKHR dramatically inhibits the proliferation of ER-dependent MCF-7 breast cancer cells. Therefore, FKHR represents a bifunctional NR intermediary protein that can act as either a coactivator or corepressor, depending on the receptor type.
引用
收藏
页码:27907 / 27912
页数:6
相关论文
共 58 条
[41]  
OSBORNE CK, 1985, CANCER RES, V45, P584
[42]   Athymic nude mouse model for the study of new antioestrogens in breast cancer [J].
Osborne, CK .
BREAST, 1996, 5 (03) :181-185
[43]   Drug therapy - Tamoxifen in the treatment of breast cancer [J].
Osborne, CK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1609-1618
[44]  
OSBORNE CK, 1996, SCI AM SCI MED S, V3, P31
[45]   Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B [J].
Rena, G ;
Guo, SD ;
Cichy, SC ;
Unterman, TG ;
Cohen, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17179-17183
[46]   The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture [J].
Scheidler, S ;
Fredericks, WJ ;
Rauscher, FJ ;
Barr, FG ;
Vogt, PK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9805-9809
[47]  
SHAPIRO DN, 1993, CANCER RES, V53, P108
[48]   Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen [J].
Smith, CL ;
Nawaz, Z ;
OMalley, BW .
MOLECULAR ENDOCRINOLOGY, 1997, 11 (06) :657-666
[49]  
SUBLETT JE, 1995, ONCOGENE, V11, P545
[50]   Negative regulation of the forkhead transcription factor FKHR by Akt [J].
Tang, ED ;
Nuñez, G ;
Barr, FG ;
Guan, KL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :16741-16746